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Dexamethasone in Hospitalized Patients with Covid-19 
— Preliminary Report
The RECOVERY Collaborative Group. Horby P, Lim WS, 
Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, 
Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, 
Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust 
SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, 
Baillie JK, Haynes R, Landray MJ. N Engl J Med 2020; Jul 
17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436
Coronavirus disease 2019 (Covid-19) is widely known 
to be related to diffuse lung damage. Glucocorticoids may 
modulate inflammation-mediated lung injury and reduce the 
rates of progression to respiratory failure and death. In this 
controlled study, comparing a range of potential treatments 
in patients who were hospitalized with Covid-19, research-
ers randomly assigned patients to receive oral or intravenous 
dexamethasone (at a dose of 6 mg once daily) for up to 10 
days or to receive standard care alone. A total of 2104 patients 
received dexamethasone and 4321 received standard care. 
Overall, 482 patients (22.9%) in the dexamethasone group and 
1110 patients (25.7%) in the standard care group died within 
28 days after randomization (age-adjusted rate ratio, 0.83; 95% 
confidence interval, 0.75 to 0.93; P<0.001). The between-group 
differences in mortality varied substantially depending on the 
level of respiratory support that the patients were receiving at 
the time of randomization. In the dexamethasone group, the 
incidence of death was lower than that in the standard care 
group among patients receiving invasive mechanical ventilation 
(29.3% vs. 41.4%; rate ratio, 0.64; 95% Confidence Interval, 
0.51 to 0.81) and among those receiving oxygen without inva-
sive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 
95% Confidence Interval 0.72 to 0.94), but not among those 
who were receiving no respiratory support at randomization. 
In conclusion, among patients hospitalized with Covid-19, the 
use of dexamethasone resulted in a lower 28-day mortality 
amongst those who were receiving either invasive mechanical 
ventilation or oxygen alone at randomization, but not among 
those receiving no respiratory support.
Efficacy of Tocilizumab in Patients Hospitalized with 
Covid-19
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Har-
vey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci 
AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, 
Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, 
Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher 
Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, 
Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza 
MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni 
ZD, Bolster MB, Kohler M, D’Silva KM, Dau J, Lockwood 
MM, Cubbison C, Weber BN, Mansour MK; BACC Bay 
Tocilizumab Trial Investigators. N Engl J Med 2020; Oct 21. 
doi: 10.1056/NEJMoa2028836
The efficacy of interleukin-6 receptor blockade with 
Tocilizumab in hospitalized patients with Covid-19 who 
are not receiving mechanical ventilation remains in doubt. 
Stone et al performed a randomized, double-blind, placebo-
controlled trial involving patients with confirmed severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 
hyperinflammatory states, and at least two of the following: 
fever >38°C), pulmonary infiltrates, or the need for sup-
plemental oxygen in order to maintain an oxygen saturation 
greater than 92%. Patients were randomly assigned to receive 
standard care plus a single dose of either tocilizumab (8 mg 
per kilogram of body weight) or placebo. They enrolled 243 
patients; 141 (58%) were men, and 102 (42%) were women. 
The median age was 59.8 years (range, 21.7 to 85.4), and 45% 
of the patients were Hispanic or Latino. The hazard ratio for 
intubation or death in the tocilizumab group as compared with 
the placebo group was 0.83 (95% confidence interval, 0.38 
to 1.81; P=0.64), and the hazard ratio for disease worsening 
was 1.11 (95% Confidence Interval, 0.59 to 2.10; P=0.73). At 
14 days, 18.0% of the patients in the tocilizumab group and 
14.9% of the patients in the placebo group had worsening of 
their disease. The median time to discontinuation of supple-
mental oxygen was 5.0 days (95% Confidence Interval, 3.8 to 
7.6) in the tocilizumab group and 4.9 days (95% Confidence 
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Interval, 3.8 to 7.8) in the placebo group (P=0.69). At 14 days, 
24.6% of the patients in the tocilizumab group and 21.2% of 
the patients in the placebo group were still receiving sup-
plemental oxygen. Interestingly, patients on tocilizumab had 
fewer serious infections than patients who received placebo. 
Tocilizumab was not effective for preventing intubation or 
death in moderately ill hospitalized patients with Covid-19. 
Nevertheless, some benefit or harm cannot be ruled out as 
the confidence intervals for efficacy comparisons were wide.
Effect of Hydroxychloroquine in Hospitalized Patients 
with Covid-19
The RECOVERY Collaborative Group. Horby P, Mafham 
M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, 
Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, 
Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, 
Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan 
K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, 
Landray MJ. N Engl J Med; 2020 Oct 8:NEJMoa2022926. 
doi: 10.1056/NEJMoa2022926
Hydroxychloroquine and chloroquine have been suggested 
as potential treatments for Covid-19 on the basis of their in 
vitro activity and data from some uncontrolled studies. In this 
randomized, controlled, study comparing a range of possible 
treatments with standard care in patients hospitalized with 
Covid-19, researchers randomly assigned 1561 patients to 
receive hydroxychloroquine and 3155 to receive standard 
care. Death within 28 days occurred in 421 patients (27.0%) 
in the hydroxychloroquine group and in 790 (25.0%) in the 
usual-care group (rate ratio, 1.09; 95% confidence interval, 
0.97 to 1.23; P=0.15). The results suggest that patients in the 
hydroxychloroquine group were less likely to be discharged 
from the hospital alive within 28 days than those in the 
usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% 
Confidence Interval, 0.83 to 0.98). Among the patients who 
were not undergoing mechanical ventilation at baseline, those 
in the hydroxychloroquine group had a higher frequency of 
invasive mechanical ventilation or death (30.7% vs. 26.9%; 
risk ratio, 1.14; 95% Confidence Interval 1.03 to 1.27). There 
was a small numerical excess in cardiac deaths, but no differ-
ence in the incidence of new major cardiac arrhythmia among 
patients who were treated with hydroxychloroquine. To sum 
up, among patients hospitalized with Covid-19, those who 
received hydroxychloroquine did not have a lower incidence 
of death at 28 days than those who received standard care.
Remdesivir for the Treatment of Covid-19 - Final Report
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman 
BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline 
S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, 
Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, 
Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios 
GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, 
Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Bur-
gess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak 
S, Lane HC; ACTT-1 Study Group Members. N Engl J Med 
2020; Oct 8:NEJMoa2007764. doi: 10.1056/NEJMoa2007764
Beigel et al conducted a double-blind, randomized, placebo-
controlled trial of intravenous remdesivir in adults hospital-
ized with Covid-19 and evidence of lower respiratory tract 
infection. Patients were randomly assigned to receive either 
remdesivir (200 mg loading dose on day 1, followed by 100 
mg daily for up to 9 additional days) or placebo for up to 
10 days. A total of 1062 patients were included in the study 
(with 541 assigned to remdesivir and 521 to placebo). Those 
who received remdesivir had a median recovery time of 10 
days (95% confidence interval, 9 to 11), as compared with 15 
days (95% Confidence interval, 13 to 18) among those who 
received placebo. The Kaplan–Meier estimates of mortality 
were 6.7% with remdesivir and 11.9% with placebo by day 
15 and 11.4% with remdesivir and 15.2% with placebo by 
day 29. Serious adverse events were reported in 131 of the 
532 patients who received remdesivir (24.6%) and in 163 of 
the 516 patients who received placebo (31.6%). These data 
advocate that the use of remdesivir was superior to placebo 
in terms of shortening the time to recovery in adults who 
were hospitalized with Covid-19 and had evidence of lower 
respiratory tract infection.
